![](/uploads/hero-insight-wide-image/_2400x960_crop_center-center_82_line/true-rx_img_white-paper_ozempic-hype-helpful.jpg)
With a staggering 42% of adults grappling with obesity, the GLP-1 receptor agonists have emerged as a promising trend. However, these medications can be costly. How can employers cope with these costs and enhance employee health? This guide will show you:
- An overview of GLP-1 drugs, which ones are approved for weight loss, and what clinical trial numbers say about effectiveness
- Obesity prevalence by state
- Plan parameters to consider